bis(2-(5-methoxy-1H-indol-3-yl)ethan-1-aminium) (2E)-but-2-enedioate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: bis(2-(5-methoxy-1H-indol-3-yl)ethan-1-aminium) (2E)-but-2-enedioate
• 英文别名: (E)-but-2-enedioic acid;2-(5-methoxy-1H-indol-3-yl)ethanamine
• 化学式: C₄H₄O₄*2C₁₁H₁₄N₂O
• 分子量: 496.563
• InChiKey: XSFMPYDOHNPOAU-WLHGVMLRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.39
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  126
• 氢给体数：
  4
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  5-甲氧基色胺 、 富马酸 以 甲醇 、 乙醚 为溶剂， 反应 60.0h， 生成 bis(2-(5-methoxy-1H-indol-3-yl)ethan-1-aminium) (2E)-but-2-enedioate
  参考文献：
  名称：

  Alpha-ethyltryptamines as dual dopamine–serotonin releasers

  摘要：

  The dopamine (DA), serotonin (5-HT), and norepinephrine (NE) transporter releasing activity and serotonin-2A (5-HT2A) receptor agonist activity of a series of substituted tryptamines are reported. Three compounds, 7b, (+)-7d and 7f, were found to be potent dual DA/5-HT releasers and were > 10-fold less potent as NE releasers. Additionally, these compounds had different activity profiles at the 5-HT2A receptor. The unique combination of dual DA/5-HT releasing activity and 5-HT2A receptor activity suggests that these compounds could represent a new class of neurotransmitter releasers with therapeutic potential. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.07.062

文献信息

• Compounds with 5-ht2 and 5-ht1a agonist activity for treating glaucoma
  申请人：——

  公开号：US20030114512A1

  公开（公告）日：2003-06-19

  Compounds with both 5-HT 2 and 5-HT 1A agonist activity which are useful for lowering and controlling IOP and the treatment of glaucomatous optic neuropathy.

  同时具有 5-HT 2 和 5-HT 1A 具有 5-HT 2 和 5-HT 1A 激动剂活性的化合物，可用于降低和控制眼压以及治疗青光眼性视神经病变。
• COMPOUNDS WITH 5-HT 2 AND 5-HT 1A AGONIST ACTIVITY FOR TREATING GLAUCOMA
  申请人：Alcon, Inc

  公开号：EP1263434A1

  公开（公告）日：2002-12-11
• [EN] COMPOUNDS WITH 5-HT2 AND 5-HT1A AGONIST ACTIVITY FOR TREATING GLAUCOMA<br/>[FR] COMPOSES A ACTIVITE AGONISTE SUR LES RECEPTEURS 5-HT2 ET 5-HT1A DESTINES AU TRAITEMENT DU GLAUCOME
  申请人：ALCON UNIVERSAL LTD

  公开号：WO2001070223A1

  公开（公告）日：2001-09-27

  Compounds with both 5-HT2 and 5-HT1A agonist activity which are useful for lowering and controlling IOP and the treatment of glaucomatous optic neuropathy.
• TRYPTAMINE DERIVATIVES
  申请人：[en]CAAMTECH, INC.

  公开号：WO2024138007A2

  公开（公告）日：2024-06-27

  This disclosure relates to 2-(5-methoxy-1H-indol-3-yl)ethanamine (5-methoxytryptamine or 5-MeO-T), crystalline 5-MeO-T, bis(2-(5-methoxy-1H-indol-3-yl)ethan-1-aminium) (2E)-but-2-enedioate dihydrate (5-methoxytryptammonium fumarate dihydrate or 5-MeO-T fumarate dihydrate), crystalline 5-MeO-T fumarate dihydrate, [2-(5-chloro-1H-indol-3-yl)ethyl]dimethyl(propan-2-yl)azanium iodide (5-chloro-N,N-dimethyl-N-isopropyltryptammonium iodide or 5-CI-DMiPT iodide), crystalline 5-CI-DMiPT iodide, [2-(5-chloro-1H-indol-3-yl)ethyl]bis(propan-2-yl)amine (5-chloro-N,N-diisopropyltryptamine or 5-CI-DiPT), crystalline 5-CI-DiPT,N,N-dimethyl-2-oxo-2-(4-phenylmethoxy-1H-indol-3-yl)acetamide (N,N-dimethyl-α-oxo-4-(phenylmethoxy)-1H-indole-3-acetamide), crystallineN,N-dimethyl-α-oxo-4-(phenylmethoxy)-1H-indole-3-acetamide, and specific crystalline forms thereof, such as crystalline form 1 of 5-MeO-T, crystalline form 1 of 5-MeO-T fumarate dihydrate, crystalline form 1 of 5-CI-DMiPT iodide, crystalline form 1 of 5-CI-Di PT, and crystalline form 1 of N,N-dimethyl-α-oxo-4-(phenylmethoxy)-1H-indole-3-acetamide, to compositions containing the same, and to method of treatment using them.